Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) does about 3.77M shares in volume on a normal day but saw 1804733 shares change hands in the recent trading day. The company now has a market cap of 32.26M USD. Its current market price is $5.15, marking no change compared to the previous close of $5.15. The 52 week high reached by this stock is $19.30 whilst the lowest price level in 52 weeks is $1.08.
Sonnet BioTherapeutics Holdings Inc (SONN) has a 20-day trading average at $4.58 and the current price is -73.32% off the 52-week high compared with 376.85% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.55 and its 200-day simple moving average is $2.36. If we look at the stock’s price movements over the week, volatility stands at 24.61%, which increases to 35.92% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 54.01 to suggest the stock is neutral.
The consensus objective for the share price is $20.00, suggesting that the stock has a potential upside of 74.25% over the period.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The current price level is 12.39%, 101.60%, and 117.98% away from its SMA20, SMA50, and SMA200 respectively, with the SONN price moving below the 50-day SMA on current market day. Sonnet BioTherapeutics Holdings Inc (SONN) stock is down -47.29% over the week and 332.77% over the past month. Its price is -25.15% year-to-date and 252.74% over the past year.
To reach the target analysts have set, the stock logically needs to grow 74.25 percent from here.
Outstanding shares total 3.33M with insiders holding 1.76% of the shares and institutional holders owning 2.65% of the company’s common stock. The company has a return on investment of -2006.15% and return on equity of -714.96%. The beta has a value of 1.04. Price to book ratio is 24.29 and price to sales ratio is 32.26.
